Clinical Trial

Hydrogen Water Intervention With Heart Rate Variability as an Outcome Biomarker in ME/CFS

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated June 8, 2025 (before its estimated May 31, 2026 completion). Its status may not reflect the trial's current state.
Summary
The goal of this clinical trial is to learn if the OTC supplement, hydrogen water, works to treat the fatigue-related symptoms and functional limitations in adults with myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). It will also examine if heart rate variability (HRV) can be used to predict who will benefit from the hydrogen water treatment. The main questions it aims to answer are: Does the OTC supplement, hydrogen water, work to reduce the fatigue-related symptoms and improve functioning in participants who have ME/CFS? Can HRV be used to predict who will benefit from treatment with hydrogen water?
Trial Details
NCT Number NCT07009691
Lead Sponsor Stony Brook University
Conditions Chronic Fatigue Syndrome
Enrollment 50 participants
Start Date 2025-06-09
Primary Completion 2026-05-31 (estimated)
Study Completion 2026-05-31 (estimated)
Updated on ClinicalTrials.gov 2025-06-08